Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 2/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | TNF | P01375 | 1/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 5/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30961612 | 1.00 | TSHR (0.48) | TSHRGSK3BTRPA1SLC6A2SLC6A4 | |
| SCHEMBL11615116 | 0.94 | GSK3B (0.50) | TSHRGSK3BTRPA1SLC6A2SLC6A4 | |
| SCHEMBL1500561 | 0.91 | GSK3B (0.45) | TSHRGSK3BTRPA1ALDH1A1MAPT | |
| SCHEMBL1500593 | 0.86 | CNR1 (0.47) | CNR1CNR2 | |
| SCHEMBL7522165 | 0.82 | TSHR (0.54) | TSHRGSK3BTRPA1ALDH1A1 | |
| SCHEMBL3882898 | 0.82 | GSK3B (0.50) | TSHRGSK3BTRPA1SLC6A2SLC6A4 | |
| SCHEMBL30583585 | 0.78 | GSK3B (0.47) | GSK3BENPP2CNR1CNR2 | |
| SCHEMBL27948985 | 0.78 | GSK3B (0.51) | TSHRGSK3BTRPA1ALDH1A1MAPT | |
| SCHEMBL6965820 | 0.78 | TRPA1 (0.57) | TSHRGSK3BTRPA1ENPP2TNF | |
| SCHEMBL2058684 | 0.78 | GSK3B (0.47) | GSK3BENPP2CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020004198-A1 | Novel anti-infectives | SMITHKLINE BEECHAM CORPORATION | 2002-01-10 | — | — | US | disclosed |
| US-20010007877-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION | 2001-07-12 | — | — | US | disclosed |
| WO-2001034146-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010007877-A1 | NOVEL ANTI-INFECTIVES | CTSL, MMP8, SERPINB1 | TSHR 4747/4885GSK3B 4630/4885TRPA1 3311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.